Exercise-induced bronchospasm: Albuterol versus montelukast: Highlights of the asthma summit 2009: Beyond the guidelines

Gene Colice, William J. Calhoun

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Exercise-induced bronchospasm (EIB) involves airway obstruction with an onset shortly after exercising. It can occur in individuals without a diagnosis of asthma, but is most common in asthmatic patients (and in this scenario may be referred to a exercise-induced asthma, EIA), correlating with the patient's degree of airway hyperreactivity. While albuterol is the most commonly used rescue and prophylactic medication for EIB, the leukotriene antagonist, monetlukast, may be an appropriate choice for some patients. Clinical data have shown that once-daily treatment with montelukast (5 or 10 mg tablet) can offer protection against EIB within 3 days for some patients. Such an approach might be preferred for patients who have difficulty with inhaled medications and for children who cannot access their inhalers during the school day. Montelukast also may be an option to reduce side effects associated with albuterol for individuals who exercise regularly.

Original languageEnglish (US)
Pages (from-to)23-30
Number of pages8
JournalWorld Allergy Organization Journal
Volume3
Issue number2
DOIs
StatePublished - Feb 2010

Keywords

  • Airway hyperreactivity
  • Albuterol
  • Asthma
  • Bronchia hyperresponsiveness
  • Exercise-induced bronchospasm
  • Exerciseinduced asthma
  • Montelukast

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Exercise-induced bronchospasm: Albuterol versus montelukast: Highlights of the asthma summit 2009: Beyond the guidelines'. Together they form a unique fingerprint.

  • Cite this